Navigation Links
Human Genome Sciences and Novozymes Announce Amendment to Albumin Fusion License Agreement
Date:5/7/2009

lies in the fact that we focus on solutions and that is why Novozymes is an ideal partner for the pharmaceutical industry. This enables Novozymes to continue to further develop albufuse(R), our proprietary albumin fusion technology, and advance our existing and new partnerships."

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. For more information about HGS, please visit the Company's web site at www.hgsi.com.

HGS and Human Genome Sciences are trademarks of Human Genome Sciences, Inc.

HGS Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements are based on Human Genome Sciences' current intent, belief and expectations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. Actual results may differ materially from these forward-looking statements because of the Company's unproven business model, its dependence on new technologies, the uncertainty and timing of clinical trials, the Company's ability to develop and commercialize products, its dependence on collaborators for services and revenue, its substantial indebtedness and lease obligations, its changing requirements and costs associated with facilities, intense competition, the uncertainty of patent and intellectual property protection, the Company's dependence on key management and key suppliers, the uncertainty of r
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Madison, WI (PRWEB) January 22, 2015 Dr. ... at the 12th annual Scripps Natural Supplements Pre-Conference seminar on ... Supplements Conference is an annual continuing education conference for health ... 15th and included the topic of probiotics in health. Dr. ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
(Date:1/22/2015)... , Jan. 22, 2015  Derma Sciences, Inc. ... company focused on advanced wound care, announces that ... tissues, have been added to the Premier, Inc. ... the opportunity for the AMNIOEXCEL® and AMNIOMATRIX® product ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... Veridex, LLC announced today,that the technology used ... (CTCs) was ranked as the top medical innovation ... academic medical center. The,ranking is based on technologies ... next year., The prestigious annual recognition follows ...
... pioneer in scalable, high performance cell loading systems, ... with industry experts on the,challenges in developing cell-based ... to the industry and will be held by ... of the respected industry experts leading this live ...
... AMDL, Inc. (Amex:,ADL), a vertically integrated pharmaceutical ... today preliminary third quarter earnings and,revised 2008 guidance ... AMDL expects gross sales to be,approximately $12.4 million ... million. Gross profit is expected to be approximately,$4.9 ...
Cached Biology Technology:Cleveland Clinic Recognizes Circulating Tumor Cell Technology as Top Medical Innovation for 2009 2Cleveland Clinic Recognizes Circulating Tumor Cell Technology as Top Medical Innovation for 2009 3MaxCyte Hosts Live Discussion with Industry Experts on the Challenges in Developing Cell-Based Screening Assays for Drug Discovery 2AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 2AMDL Announces Preliminary Third Quarter Earnings; Revises 2008 Guidance 3
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication ... success of the Wocket™ smart wallet at CES 2015 in ... as one of the "11 Hot Products at CES" in a review ... So Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) ... Wearable Technologies Market and Applications, Opportunities, Industry Analysis, ... 2014-2020" report to their offering. , ... can be worn on the user,s body and ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... The Netherlands: Ultra-fast freezing of ovarian tissue from women ... cancer treatment can lead to it being used in ... a researcher told the 25th annual conference of the ... 29 June). Dr. Sherman Silber, Director of the St. ...
... 58 km southeast of Shingu City, Japan--Deepsea Drilling Vessel ... Trough Seismogenic Zone off the Kii Peninsula of Japan. ... water depths of 2,054 meters. Following sea floor surveys, ... prevention (BOP) system into an upper section of the ...
... Amsterdam, The Netherlands: Dutch researchers have found the first evidence ... development and implantation, which was known to occur in mice ... human female embryos prior to implantation in the womb. ... of the European Society of Human Reproduction and Embryology in ...
Cached Biology News:Ovarian transplantation: New technique gives greatly improved results in this delicate operation 2First riser-drilling research operations undertaken 2Female human embryos adjust the balance of X chromosomes before implantation 2Female human embryos adjust the balance of X chromosomes before implantation 3Female human embryos adjust the balance of X chromosomes before implantation 4
... ValveBank system! Program your valve and TTL ... 98, 2000, XP using graphic 'click-and-drag' timebars. Save ... program listings, then download your programs into the ... used for programming before -- not during -- ...
... Monoclonal Anti-β-Tubulin IV Recognizes an ... sequence of β-tubulin isotype IV. ... isotypes is observed. ascites fluid ... C-terminal sequence of β-tubulin isotype ...
Sulfadimethoxine (CH-2027)...
... Mouse monoclonal [E12] to MAP1 Light Chain ... mediate the physical interactions between microtubules and components ... of a heavy chain subunit and multiple light ... is one of the light chain subunits and ...
Biology Products: